Sopherion Therapeutics, LLC, a bio-pharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it has received Fast Track Designation from the US Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet) for first-line therapy of HER2 positive metastatic breast cancer. Treatment with Myocet has already shown a reduced level of cardiotoxicity as compared to traditional doxorubicin.